| Literature DB >> 24625750 |
Jonathon Blake1, Andrew Riddell2, Susanne Theiss3, Alexis Perez Gonzalez2, Bettina Haase1, Anna Jauch3, Johannes W G Janssen3, David Ibberson4, Dinko Pavlinic1, Ute Moog3, Vladimir Benes1, Heiko Runz5.
Abstract
Balanced chromosome abnormalities (BCAs) occur at a high frequency in healthy and diseased individuals, but cost-efficient strategies to identify BCAs and evaluate whether they contribute to a phenotype have not yet become widespread. Here we apply genome-wide mate-pair library sequencing to characterize structural variation in a patient with unclear neurodevelopmental disease (NDD) and complex de novo BCAs at the karyotype level. Nucleotide-level characterization of the clinically described BCA breakpoints revealed disruption of at least three NDD candidate genes (LINC00299, NUP205, PSMD14) that gave rise to abnormal mRNAs and could be assumed as disease-causing. However, unbiased genome-wide analysis of the sequencing data for cryptic structural variation was key to reveal an additional submicroscopic inversion that truncates the schizophrenia- and bipolar disorder-associated brain transcription factor ZNF804A as an equally likely NDD-driving gene. Deep sequencing of fluorescent-sorted wild-type and derivative chromosomes confirmed the clinically undetected BCA. Moreover, deep sequencing further validated a high accuracy of mate-pair library sequencing to detect structural variants larger than 10 kB, proposing that this approach is powerful for clinical-grade genome-wide structural variant detection. Our study supports previous evidence for a role of ZNF804A in NDD and highlights the need for a more comprehensive assessment of structural variation in karyotypically abnormal individuals and patients with neurocognitive disease to avoid diagnostic deception.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24625750 PMCID: PMC3953210 DOI: 10.1371/journal.pone.0090894
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Base-pair level characterization of clinically-identified de novo balanced chromosome abnormality (BCAs).
(A) Chromosomes 2 and 7 of the patient as visualized by GTG-banding. Breakpoint positions of BCAs reported from clinical analyses at karyotype level are indicated in red. (B,C) Graphical representation of anomalous-read (red dots) fusion positions for t(2;7) (B) and the paracentric inv(2) (C). Based on mate-pair library sequencing-identified gap positions primers were designed to amplify and validate anomalous regions by PCR and capillary sequencing at base-pair level. (D) Validation of re-annotated t(2;7) breakpoint positions by FISH with BAC-probes binding immediately adjacent to re-defined translocation sites.
Genes disrupted by validated structural rearrangements (>10 kb) in the patient.
| SV no. | revised karyotype | breakpoint start | disrupted gene | RefSeq transcript position | exon count | proposed functions | disease link | ref. | con-firmed | mRNA levels | fusion mRNA | brain expressed | patient |
| 1 |
| chr7∶135,245,984 | NUP205 | chr7∶135,242,662–135,333,499 | 43 | nuclear-cytoplasmic transport | Paget’s disease (assoc.) |
| yes | normal | yes | yes | 1.9% |
| chr2∶8,181,790 |
| chr2∶8,347,273–8,468,549 | 8 | unknown | NDD, neurodegeneration |
| yes | possibly increased | yes | n.r. | |||
| 2 |
| chr2∶22,350,265 | AC068490.2 | chr2∶22,156,208–22,753,977 | 5 | unknown | n.r. | n.r. | yes | n.d. | yes | n.r. | n.r. |
| chr2∶162,196,595 | PSMD14 | chr2∶162,164,786–162,268,228 | 12 | protein degradation | 2q24.2 syndrome (assoc.) |
| yes | normal | yes | 1.8% | |||
| 3 |
| chr2∶185,679,985 |
| chr2∶185,463,093–185,804,214 | 4 | transcription factor | NDD, schizophrenia/bipolar disorder (assoc.) |
| yes | reduced | no | yes | 38.7% |
| chr2∶188,161,779 | AC007319.1 | chr2∶187,868,001–188,419,120 | 4 | unknown | n.r. | n.r. | yes | n.d. | n.r. | n.r. | |||
| 4 |
| chr19∶54,800,252 | LILRA3 | chr19∶54,799,855–54,804,221 | 7 | immuno-receptor | prostate cancer/HDL-c (assoc.) |
| yes | n.d. | N/A | no/low | n.r. |
| chr19∶54,809,071 | N/A | N/A | N/A | N/A | N/A | N/A | yes | n.d. | N/A | N/A |
revision to clinical diagnostic reports in bold;
reported neurodevelopmental disease (NDD) genes in bold;
acc. to Huang et al., 2010 [28].
Figure 2Nucleotide-level characterization of cytogenetically visible breakpoints identifies gene fusions that encode for abnormal transcripts.
(A,B) Graphical representation of the four genes within the cytogenetically visible reciprocal translocation t(2;7)(2p25.1;q33) and the pericentric inversion inv(2)(p24.1q24.2) in which structural variants disrupt protein-coding gene regions in the patient. Sites of breakpoints are denoted by arrows. (C,D) To monitor whether predicted SV-induced fusion transcripts resulted in abnormal transcripts, total RNA from three biological replicates per proband was isolated from lymphoblasts of the patient (46,XY,t(2;7); lanes 4–6) and a healthy male control individual (46,XY; lanes 1–3). For each site of structural rearrangement mRNA-levels of both, the wildtype and/or pre−/post rearrangement transcript, as well as the predicted fusion transcript were amplified with target-specific primers by RT-PCR.
Phenotypic comparison of the patient to previously described individuals with structural variants affecting ZNF804A or LINC00299.
| symptom | patient | ZNF804A | LINC00299 | ||||
| Talkowski et al., 2012a | DECIPHER CNV cases (n = 7) | Talkowski et al., 2012b | |||||
| DGAP180 | father of DGAP180 | CNV cases (n = 7) | DGAP162 | CNV case L1 | |||
|
|
| complex chromosomal rearrangementstarting 229 kb downstream of 3′UTR | CNVs comprising multiple genes at 2q31.1–2q33.1 | CNVs comprising multiple genes at 2q31.2–2q32.3 | break in intron 6;exons 7–8 missing | deletion ofexons 7–8 | |
|
| yes | yes | yes | yes (n = 4) | yes (n = 7) | yes | yes |
|
| yes | yes | yes | yes (n = 7) | yes (n = 6) | yes | yes |
|
| yes | yes | yes | yes (n = 1) | yes (n = 3) | yes | n.r. |
|
| yes | n.r. | yes | n.r. | n.r. | n.r. | n.r. |
|
| yes | yes | yes | yes (n = 1) | yes (n = 2) | yes | n.r. |
|
| yes | yes | n.r. | n.r. | yes (n = 1) | yes (progressive) | n.r. |
|
| yes (axial, tectum) | yes (axial, Sylvianfissure) | n.r. | n.r. | n.r. | no (partial agenesisof corpus callosum) | n.r. |
|
| yes | yes | n.r. | n.r. | n.r. | yes | n.r. |
|
| no | no | no | yes (n = 3) | yes (n = 7) | no | no |
|
| yes | no | n.r. | yes (n = 1) | n.r. | no | n.r. |
|
| oligohydramnios | IUGR, prematurity, pneumonia | tics | cleft palate,microcephalus, … | cleft palate, seizures, micrognathia,… | oligohydramnios, dilated fetal kidneys, seizures, disinhibition | seizures, treated for bipolar disorder |
|
| consanguinity | family members with cognitive andspeech impairment, tics, anxiety | n.r. | n.r. | n.r. | n.r. | |
Figure 3Genome-wide analysis for cryptic SVs identifies disruption of further neurodevelopmental disease candidate genes and demonstrates reduced expression of ZNF804A in patient cells.
(A,B) Graphical representation of the three genes disrupted by an ∼10 kB deletion on chr 19 [del(19q13.4)] (A) and the cryptic paracentric inversion inv(2)(p32.1q32.1) in the patient. Sites of breakpoints are denoted by arrows. (C) Graphical representation of anomalous-read (red dots) fusion positions for the cryptic 2.49 Mb paracentric inversion on chromosome 2. Mate-pair library sequencing-predicted breakpoints 5′ and 3′ of the inversion were amplified with breakpoint-specific primers and validated at base-pair level by PCR and capillary sequencing. (D) mRNA-levels of ZNF804A and the housekeeping gene RPL19 were quantified by qRT-PCR from total RNA isolated from fibroblasts of the patient or a healthy male control and normalized to expression of beta-actin.